Consorci Sanitari De Terrassa
- Address
- lock Available on a paid plan
Neoplasms
The department is advancing treatment for a range of cancers, including breast, cervical, endometrial, colorectal, lung, and prostate malignancies, by testing new therapeutic combinations and maintenance strategies.
- Adjuvant therapy evaluation for early‑stage breast cancer
- Sequencing of biologic agents with chemotherapy in metastatic colorectal cancer
- Combination immunotherapy for resectable non‑small cell lung cancer
- Maintenance approaches in advanced endometrial cancer
- Risk‑adapted treatment for high‑risk localized prostate cancer
Consorci Sanitari De Terrassa supports 24 active trials with 25 investigators, highlighting its role in oncology research across Europe.
Cardiovascular Diseases
Research aims to improve outcomes for patients with cardiovascular disease by evaluating novel lipid‑lowering agents and anti‑inflammatory therapies.
- Lipoprotein(a) reduction and cardiovascular event prevention
- Assessment of oral versus parenteral antibiotic strategies for infective endocarditis
- Evaluation of aspirin discontinuation protocols for preeclampsia prevention
The site’s multidisciplinary team contributes to advancing heart health while collaborating with national cardiovascular networks.
Respiratory Tract Diseases
Studies focus on improving management of respiratory conditions, particularly lung cancer and related surgical outcomes.
- Post‑operative infection prevention in total joint replacement
- Evaluation of fibrin‑based adhesives to reduce esophagojejunal anastomosis dehiscence after gastrectomy
- Combination therapy trials for resectable non‑small cell lung cancer
These trials integrate surgical expertise with medical oncology to enhance patient recovery and survival.
Immune System Diseases
The unit investigates innovative immunomodulatory approaches for immune‑mediated disorders, including allergic diseases and autoimmune neuro‑psychiatric conditions.
- Allergen immunotherapy for house‑dust mite‑related rhinitis and asthma
- Subcutaneous immunotherapy with Cup a 1 protein for allergic rhinoconjunctivitis
- Complement component 5 inhibition for geographic atrophy
- KarXT combination therapy for agitation in Alzheimer’s disease
By targeting key immune pathways, the site contributes to safer and more effective treatments for chronic allergic and neuro‑inflammatory conditions.
Musculoskeletal Diseases
Clinical work seeks to lower infection risk and improve healing in musculoskeletal surgery, especially joint replacement procedures.
- Comparison of antiseptic irrigation solutions versus saline in total hip and knee arthroplasty
- Evaluation of local vancomycin application to prevent prosthetic joint infection
- Outpatient oral antibiotic therapy as an alternative to parenteral treatment for surgical infections
These investigations aim to reduce postoperative complications and shorten hospital stays for orthopedic patients.
Digestive System Diseases
Trials address acute and chronic conditions of the gastrointestinal tract, testing fluid management and surgical adjuncts.
- Lactated Ringer’s solution versus normal saline for acute pancreatitis resuscitation
- Fibrin‑based adhesive use to prevent esophagojejunal anastomosis leaks after total gastrectomy
- Sequencing of chemotherapy and targeted agents in metastatic colorectal cancer
The research combines critical care and surgical expertise to enhance recovery and long‑term outcomes.
Eye Diseases
Focused studies aim to slow progression of age‑related macular degeneration and its advanced form, geographic atrophy.
- Complement inhibition therapy to reduce lesion growth in geographic atrophy
- Evaluation of novel subcutaneous agents for macular disease management
By targeting underlying complement pathways, the site seeks to preserve vision in affected patients.
Nervous System Diseases
Research explores therapies for neurological disorders, including migraine and Alzheimer’s‑related agitation.
- Botulinum toxin (Xeomin) injections for chronic migraine prevention
- Xeomin treatment for episodic migraine reduction
- KarXT plus KarX‑EC combination for agitation in Alzheimer’s disease
These trials aim to improve quality of life for patients with debilitating headache and neuro‑psychiatric symptoms.
Mental Disorders
The department evaluates novel pharmacologic options for psychiatric conditions, focusing on agitation associated with dementia.
- KarXT plus KarX‑EC versus placebo for agitation in Alzheimer’s disease
The study seeks to provide safer, more effective management of behavioral symptoms in elderly patients.
Bacterial Infections and Mycoses
Clinical investigations target resistant bacterial infections, especially urinary and prosthetic infections.
- Oral fosfomycin‑tromethamol for multidrug‑resistant Escherichia coli prostatitis
- Outpatient oral antibiotic therapy versus parenteral treatment for infective endocarditis
By exploring oral alternatives, the trials aim to reduce hospitalization time while maintaining therapeutic efficacy.
Allergic Rhinitis and Asthma
Studies evaluate allergen‑specific immunotherapies and symptom‑relief strategies for allergic rhinitis with or without asthma.
- Subcutaneous immunotherapy with house‑dust mite extracts
- Grass and olive pollen immunotherapy using mobile‑app symptom tracking
- Cup a 1 protein immunotherapy for Cupressaceae pollen allergy
- Comparison of oral antihistamine regimens for moderate‑to‑severe rhinitis
These projects aim to reduce symptom burden and improve daily functioning for allergy sufferers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
- 1LETI Pharma S.L.U.3active
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1LETI Pharma S.L.U.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorci Sanitari De Terrassa
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma | LETI Pharma S.L.U. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 2 | Unknown | 2018-09-21 | 2018-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.